Valeant Pharmaceuticals To Hold Investor Conference Call On October 26, 2015

Valeant Pharmaceuticals International, Inc.

today announced that it will host a conference call and a live webcast along with a slide presentation on Monday, October 26, 2015 at 8:00 a.m. ET (5:00 a.m. PT). The purpose of the call will be to lay out the facts including allegations made against our company regarding our relationship with Philidor and R&O, our accounting practices, and channel stuffing that contain numerous errors, unsupported speculation and incorrect interpretations of facts and circumstances to the detriment of the shareholders of the Company. Participants on the call will include: Norma Provencio, Board Member, Chairman Audit and Risk Committee Theo Melas-Kyriazi, Board Member, Member Audit and Risk Committee Katharine Stevenson, Board Member, Member Audit and Risk Committee Howard Schiller, Board Member, former Chief Financial Officer Robert Hale, Board Member, Partner of ValueAct Capital J. Michael Pearson, Chairman and Chief Executive Officer Robert Chai-Onn, General Counsel Robert Rosiello, Chief Financial Officer Tanya Carro, Corporate Controller Ari Kellen, Company Group Chairman "We look forward to our call on Monday where we will address and refute recent allegations," stated J. Michael Pearson, chairman and chief executive officer. stated J. Michael Pearson, chairman